Please assess the completion status of the following clinical trial:

Trial Title: MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically / cytologically verified, non-resectable, recurrent, or metastatic biliary tract carcinoma including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma~* Patients who have previously treated with gemcitabine-based chemotherapy (Prior treatment regimen up to 2 is allowed)~* Patients must have measurable or evaluable disease by RECIST 1.1~* Eastern Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1~* Age ≥ 20 years~* Adequate bone marrow function defined as: Hb ≥ 8 g/dl, absolute neutrophil count (ANC) ≥ 1500/microliter (mcL), Platelets ≥ 100 x10\^3/mcL~* Adequate renal function defined as serum creatinine \< 1.6 mg/dl and/or measured creatinine clearance from 24-hour urine collection of ≥ 60 ml/min~* Adequate hepatic function defined as total bilirubin ≤ 2 mg/dl, alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)~* Patients with biliary obstruction can join if bilirubin corrects to required limit after adequate biliary drainage~* Women of childbearing potential must have a negative pregnancy test within 7 days prior to study treatment~* Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Evidence of another active cancer that may influence patient outcome, except for nonmelanoma skin carcinoma, melanoma in-situ, in-situ carcinoma of the cervix curatively treated, treated superficial bladder cancer, and adenocarcinoma of the prostate that has been surgically treated with a post-treatment prostate surface antigen (PSA) that is non-detectable~* Known brain metastases or primary central nervous system tumors with seizures that are not well controlled with standard medical therapy~* Uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements~* Known HIV positive patient~* Significant cardiovascular disease including congestive heart failure (New York Heart Association Class II or higher) or active angina pectoris~* Uncontrolled diabetes mellitus~* History of a myocardial infarction within 6 months~* History of a stroke or transient ischemic attack within 6 months~* Clinically significant peripheral vascular disease~* Major surgical procedure within 4 weeks~* Uncontrolled infection~* Known or suspected allergy to capecitabine~* Pregnant (positive pregnancy test)~* Breast-feeding should be discontinued if a nursing mother is to be treated on clinical trial~* Any condition that impairs patient's ability to swallow whole pills~* Malabsorption problem that may limit or inhibit the absorption of MEK162~* History of any organ or bone marrow transplant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1 part (Type: EXPERIMENTAL): to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
- Expansion part (Type: EXPERIMENTAL): to assess the efficacy (PFS) of MEK162+Capecitabine combination

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete